276 related articles for article (PubMed ID: 19275511)
1. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
[TBL] [Abstract][Full Text] [Related]
2. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
5. Targeting oncogenic ALK: a promising strategy for cancer treatment.
Grande E; Bolós MV; Arriola E
Mol Cancer Ther; 2011 Apr; 10(4):569-79. PubMed ID: 21474455
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
7. The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer.
Perez-Pinera P; Garcia-Suarez O; Menendez-Rodriguez P; Mortimer J; Chang Y; Astudillo A; Deuel TF
Biochem Biophys Res Commun; 2007 Oct; 362(1):5-10. PubMed ID: 17706593
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
Perez-Pinera P; Zhang W; Chang Y; Vega JA; Deuel TF
J Biol Chem; 2007 Sep; 282(39):28683-28690. PubMed ID: 17681947
[TBL] [Abstract][Full Text] [Related]
9. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
[TBL] [Abstract][Full Text] [Related]
10. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
Mathivet T; Mazot P; Vigny M
Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
[TBL] [Abstract][Full Text] [Related]
13. Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase.
Bacchiocchi R; Baldanzi G; Carbonari D; Capomagi C; Colombo E; van Blitterswijk WJ; Graziani A; Fazioli F
Blood; 2005 Sep; 106(6):2175-82. PubMed ID: 15928040
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
16. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
17. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
Stylianou DC; Auf der Maur A; Kodack DP; Henke RT; Hohn S; Toretsky JA; Riegel AT; Wellstein A
Oncogene; 2009 Sep; 28(37):3296-306. PubMed ID: 19633684
[TBL] [Abstract][Full Text] [Related]
18. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase.
Kuo AH; Stoica GE; Riegel AT; Wellstein A
Oncogene; 2007 Feb; 26(6):859-69. PubMed ID: 16878150
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
Mesaros EF; Ott GR; Dorsey BD
Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of anaplastic lymphoma kinase: a patent review.
Milkiewicz KL; Ott GR
Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]